Key result
Second-generation drug-eluting stents significantly reduced the incidence of stent thrombosis at 30 days compared with bare-metal stents (OR 0.36; 95% CI 0.15-0.82).
Why the study?
Does second-generation DES reduce stent thrombosis compared to bare-metal stents in patients undergoing primary PCI for STEMI?
Population
12,866 patients from 21 randomized trials undergoing primary percutaneous coronary intervention for…
Comparison
Second-generation drug-eluting stents (DES) vs Bare-metal stents (BMS)
Design
Meta-analysis
Follow-up
1 year
Authors
Loading...
Supports second-generation DES over bare-metal stents in STEMI primary PCI; confirms lower 30-day stent thrombosis risk.
Meta-Analysis (n=12,866)
Does second-generation DES reduce stent thrombosis compared to bare-metal stents in patients undergoing primary PCI for STEMI?
Odds Ratio: 0.36 (95% CI 0.15–0.82)
Network meta-analysis demonstrates that second-generation DES significantly reduces stent thrombosis, myocardial infarction, and target vessel revascularization compared to bare-metal stents in primary PCI for STEMI.
Philip et al. (2013) conducted a meta-analysis in ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention (n=12,866). Second-generation drug-eluting stents vs. Bare-metal stents was evaluated on Stent thrombosis at 30 days (OR 0.36, 95% CI 0.15-0.82). Second-generation drug-eluting stents significantly reduced the incidence of stent thrombosis at 30 days compared with bare-metal stents (OR 0.36; 95% CI 0.15-0.82).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: